written on 09.06.2014

Analysts: Biogen's second long-acting hemophilia med headed for blockbuster strata


With Friday's FDA nod for Eloctate, Biogen Idec won approval for its second long-acting hemophilia treatment this year. But while both will shake up their respective markets, this one–a hemophilia A treatment–will be where the money is.

Latest Reports